Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T-cells for treatment of leukemia and lymphoma. There is now rapid growth in research on the therapeutic uses of CAR T-cells.
To help researchers develop efficient CAR T-cells, we aim to provide many innovative solutions, such as recombinant cell line expressing cancer antigens, or recombinant versions of these antigens. Developed by BPS Bioscience, these products will help scientists to more precisely monitor the effectiveness of the engineered CAR T to detect and bind to a specific cancer antigen.